Derfuss et al |
Advances in oral immunomodulating therapies in relapsing multiple sclerosis |
Lancet Neurol 2020; 19: 336–47 |
|
Comi et al |
Evolving concepts in the treatment of relapsing multiple sclerosis |
Lancet 2017; 389: 1347–56 |
|
McGinley et al |
Diagnosis and Treatment of Multiple Sclerosis A Review |
JAMA. 2021;325(8):765-779. doi:10.1001/jama.2020.26858 |
|
Amato et al |
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis |
BRAIN 2020: 143; 3013–3024 |
|
Kalincik et al |
Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years |
Neurology 2020 |
|
Roy et ACNS |
Sphingosine 1‑Phosphate Receptor Modulators for Multiple Sclerosis |
Drugs2021 |
|
Chun et al |
Sphingosine 1‑phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects |
Drugs (2021) 81:207–231 |
|
Comi et al |
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial |
Lancet Neurol 2019; 18: 1009–20 |
|
Cohen et al |
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial |
Lancet Neurol 2019; 18: 1021–33 |
|
Rocca et al |
Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis |
Neurology. 2021 Mar 16;96(11):e1561-e1573 |
|
Eijlers et al |
Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis |
Neurology. 2019 Oct 1;93(14):e1348-e1359 |
|
Manca et al |
Multiple brain networks support processing speed abilities of patients with multiple sclerosis |
Postgrad Med. 2019 Sep;131(7):523-532. doi: 10.1080/00325481.2019.1663706. Epub 2019 Sep 16 |
|
Meca-Lallana et al |
Cognitive impairment in multiple sclerosis: diagnosis and monitoring |
Neurol Sci. 2021 Apr 1. doi: 10.1007/s10072-021-05165-7. Online ahead of print |
|
Lakin et al |
Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review |
Neurol Ther. 2021 Apr 20. doi: 10.1007/s40120-021-00239-2. Online ahead of print |
|
Amato et al |
Treatment of cognitive impairment in multiple sclerosis: position paper |
J Neurol. 2013 Jun;260(6):1452-68. doi: 10.1007/s00415-012-6678-0. Epub 2012 Nov 23 |
|
Vollmer et al |
Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review |
Neurol Sci. 2016 Feb;37(2):165-79. doi: 10.1007/s10072-015-2400-1. Epub 2015 Nov 4 |
|
DeLuca et al |
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS |
Mult Scler Relat Disord. 2021 Feb;48:102673. doi: 10.1016/j.msard.2020.102673. Epub 2020 Dec 10 |
|
Filippi et al |
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines |
Lancet Neurol. 2016 Mar;15(3):292-303. doi: 10.1016/S1474-4422(15)00393-2. Epub 2016 Jan 26 |
|
Filippi et al |
Identifying Progression in Multiple Sclerosis: New Perspectives |
Ann Neurol. 2020 Sep;88(3):438-452. doi: 10.1002/ana.25808. Epub 2020 Jul 6 |
|
Filippi et al |
Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines |
Brain. 2019 Jul 1;142(7):1858-1875. doi: 10.1093/brain/awz144 |
|
Chard et al |
Mind the gap: from neurons to networks to outcomes in multiple sclerosis |
Nat Rev Neurol. 2021 Mar;17(3):173-184. doi: 10.1038/s41582-020-00439-8. Epub 2021 Jan 12 |
|
Gasperini et al |
Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge |
Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26 |
|